Top Tips For Spanish Biotechs Hoping To Make It Big
Spain has developed a reputation for excellent science and a top destination in Europe to conduct clinical trials. Now its budding biotechs are looking to make headway in choppy commercial waters as the sector continues to mature.
Scrip - October 7, 2026

‘Nature’s Ozempic’ And Ashwagandha Top Trending Supplements List Across US, Europe In 2026
Ashwagandha tops consumer search interest across the US and five European markets, according to HBW Insight's Google Trends analysis of 50 supplements. Iron, sleep and CoQ10 complete the top four, while berberine ranks seventh, despite facing growing regulatory scrutiny in Europe.
HBW Insight - October 7, 2026

Adalvo Tightens GLP-1 Focus With A New Dedicated Business Unit
Malta-based B2B company Adalvo has announced plans to establish a new dedicated GLP-1 business unit focused on advancing opportunities by increasing the speed of decision making and strengthening accountability.
Generics Bulletin - October 7, 2026

AESGP Switch Day: Self-Medication A ‘Strategic’ Priority For Europe, Commission Says
EU Health Commissioner Olivér Várhelyi told AESGP's first Switch Day that self-medication is "strategic" for Europe, as pharma reform bringing new shortage duties for OTC companies nears entry into force.
HBW Insight - October 7, 2026

Becton Dickinson’s $19bn Deal Sets Out What Medtech Tariff Relief May Cost
BD has struck a $19bn investment deal with the Trump administration to secure relief from future Section 232 medtech tariffs and President Trump says duties will be in place by year-end. The deal offers the first clues to where the probe is heading.
Medtech Insight - October 7, 2026

Lycia Plans IPO To Fund Next-Generation Protein Degraders
The South San Francisco company is developing therapies that target extracellular proteins, and its lead candidate is a food allergy therapy.
Scrip - October 7, 2026

Zydus And MSN Are First To Challenge Adempas In US
Zydus Lifesciences and MSN Laboratories have partnered for the first US launch of a generic rival to Bayer’s Adempas (riociguat) tablets.
Generics Bulletin - October 7, 2026

Formycon Targets 20% Process Efficiency Gain With AI Tools
As artificial intelligence adoption becomes standard across the biosimilars sector, Formycon is integrating AI tools as part of its financial recovery strategy.
Generics Bulletin - October 7, 2026

Vertex CDIO On Operating Model Shifts And The Case For ‘Unreasonable Goals’
Vertex Pharmaceuticals’ CDIO Agam Upadhyay outlines the firm’s three-pronged AI approach, the value realization framework keeping every deployment accountable and the CEO's seemingly impossible ask that led to striking AI win.
Scrip - October 7, 2026

European Medtech Growth Slows To 1.8%, As Industry Pushes For Market That Can Match US
European medical device market growth slowed to 1.8% in 2025 from 6.0%, and the number of medtech companies fell for the first time in the report’s history, according to MedTech Europe’s 2026 Facts & Figures. The association tied the data to its call for streamlined EU regulation.
Medtech Insight - October 7, 2026

BioBytes: AI-Related Deals In Q3 ‘26
AI biotech funding in Q3 showed that capital is spreading across drug discovery, clinical development and the infrastructure connecting AI to the lab.
Scrip - October 7, 2026

MIT’s Barzilay Wants AI To Predict Who Responds
Since her 2014 breast cancer diagnosis, MIT's Regina Barzilay has built artificial intelligence tools for screening and drug discovery. Now she is developing AI to predict which patients will respond to which treatments.
In Vivo - October 7, 2026

CRN Back To Court Where It Started Challenging New York Age-Restricted Supplement Sales Law
Supreme Court denial of appeals to hear more than 700 cases during its current term includes rejection of CRN’s petition for a writ of certiorari in its complaint against New York restricting sales of weight loss and bodybuilding supplements to consumers 18 and older.
HBW Insight - October 7, 2026

Amazon, Walmart Warned About STI Treatment Claims For OTC Topicals, Including Homeopathics
Warnings mark a first for FDA about OTC topicals rendered unapproved due to labeling for STI treatment and latest action to remind consumer health products sector that since 2022 agency made homeopathics subject to same regulations as other types of drugs.
HBW Insight - October 7, 2026